KYNTHEUM (brodalumab), interleukin inhibitor immunosuppressant
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Jul 19 2018
Reason for request
Inclusion
High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by:
failure of at least two treatments including non-biological systemic treatments and light therapy
and an extensive form and/or significant psychosocial impact
but no proven clinical added value compared to COSENTYX and TALTZ.
Insufficient clinical benefit to justify reimbursement for other forms.
- KYNTHEUM is an IL17 receptor A inhibitor that has been granted a marketing authorisation for moderate to severe plaque psoriasis in adults requiring systemic treatment.
Similar to the other IL17 antagonists, COSENTYX and TALTZ, it has demonstrated its superiority over STELARA.
KYNTHEUM is a systemic treatment to be reserved for the treatment of plaque psoriasis in adults, for patients with severe, chronic plaque psoriasis, defined by:
failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy
and an extensive form and/or significant psychosocial impact.
Clinical Benefit
Substantial |
- |
Insufficient |
Clinical Added Value
no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments